Immunotherapy for metastatic gastric cancer

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Tables (1-1)

Sum=92

Publishing Process of This Article

Item

Count

Browse

Download

Sum=2

Nov 27, 2024 (publication date) through Nov 5, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Surg. Nov 27, 2024; 16(11): 3408-3412
Published online Nov 27, 2024. doi: 10.4240/wjgs.v16.i11.3408

Table 1 Clinical trials of immune checkpoint inhibitor treatment for metastatic gastric cancer

Clinical trial	Treatment	Phase
Attraction-2	Nivolumab	III
Keynote-059	Pembrolizumab	II
JAVELIN Gastric 300	Avelumab	III
Keynote-062	Pembrolizumab combined with chemotherapy	III
Checkmate-649	Nivolumab combined with chemotherapy	III
Attraction-4	Nivolumab combined with chemotherapy	III
Keynote-811	Pembrolizumab combined with trastuzumab and chemotherapy	III

Citation: Li CF, Lian LL, Li QR, Jiao Y. Immunotherapy for metastatic gastric cancer. World J Gastrointest Surg 2024; 16(11): 3408-3412
URL: https://www.wjgnet.com/1948-9366/full/v16/i11/3408.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i11.3408